$1.71
8.06% yesterday
Nasdaq, Sep 03, 10:13 pm CET
ISIN
KYG6096M1069
Symbol
APM

Aptorum Group Limited Class A Stock price

$1.71
+0.29 20.42% 1M
+0.82 91.70% 6M
-1.09 38.93% YTD
-1.32 43.56% 1Y
-11.89 87.43% 3Y
-15.29 89.94% 5Y
-141.79 98.81% 10Y
-141.79 98.81% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.15 8.06%
ISIN
KYG6096M1069
Symbol
APM
Industry

Key metrics

Basic
Market capitalization
$12.2m
Enterprise Value
$14.7m
Net debt
$2.4m
Cash
$870.0k
Shares outstanding
5.6m
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
- | 0.1
EV/Sales
- | 0.1
EV/FCF
negative
P/B
0.6
Financial Health
Equity Ratio
131.0%
Return on Equity
-20.2%
ROCE
-31.1%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $146.8m
EBITDA
$-3.4m | $15.0m
EBIT
$-3.7m | $114.5m
Net Income
$-4.3m | $334.3m
Free Cash Flow
$-1.2m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
61.6% | 856.2%
EBIT
63.3% | 5,213.0%
Net Income
-51.4% | 7,929.0%
Free Cash Flow
84.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | 10.3%
EBIT
-
Net
- | 227.7%
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.2
Short interest
3.4%
Employees
3
Rev per Employee
$0.0
Show more

Is Aptorum Group Limited Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Aptorum Group Limited Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Aptorum Group Limited Class A forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Aptorum Group Limited Class A forecast:

Buy
83%
Hold
17%

Financial data from Aptorum Group Limited Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 1.47 1.47
67% 67%
-
- Research and Development Expense 1.82 1.82
50% 50%
-
-3.41 -3.41
62% 62%
-
- Depreciation and Amortization 0.26 0.26
77% 77%
-
EBIT (Operating Income) EBIT -3.67 -3.67
63% 63%
-
Net Profit -4.27 -4.27
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptorum Group Limited Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptorum Group Limited Class A Stock News

Neutral
GlobeNewsWire
14 days ago
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that Dia...
Neutral
Seeking Alpha
22 days ago
Andean Precious Metals Corp. (OTCQX:ANPMF) Q2 2025 Earnings Conference Call August 13, 2025 9:00 AM ET Company Participants Alberto Morales - Founder, CEO & Executive Chairman Amanda Mallough - Corporate Participant Dom Kizek - Corporate Participant Juan Carlos Sandoval - Chief Financial Officer Yohann Bouchard - President & Director Conference Call Participants Allison Carson - Desjardins Secu...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq's minimum bi...
More Aptorum Group Limited Class A News

Company Profile

Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO Ian Huen
Employees 3
Founded 2010
Website www.aptorumgroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today